Drug Interaction Report
1 drug interaction and 14 additional warnings found for the following 2 drugs:
- Banflex (orphenadrine)
- remimazolam
Drug interactions
Moderate drug interactions
Moderate:orphenadrine remimazolam
Applies to: Banflex (orphenadrine), remimazolam
Using orphenadrine together with remimazolam may increase side effects such as:
- dizziness
- drowsiness
- confusion
- difficulty concentrating
Some people, especially the elderly, may also experience impairment in thinking, judgment, and motor coordination.
What to do: You should avoid or limit the use of alcohol while being treated with these medications. Also avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medications affect you.
Talk to your doctor if you have any questions or concerns. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Food/lifestyle interactions
Moderate food/lifestyle interactions
Moderate:Food/Lifestyle orphenadrine
Applies to: Banflex (orphenadrine)
Alcohol can increase the nervous system side effects of orphenadrine such as:
- dizziness
- drowsiness
- difficulty concentrating
Some people may also experience impairment in thinking and judgment.
You should avoid or limit the use of alcohol while being treated with orphenadrine.
Do not use more than the recommended dose of orphenadrine, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you.
Talk to your doctor or pharmacist if you have any questions or concerns.
Moderate:Food/Lifestyle remimazolam
Applies to: remimazolam
Alcohol can increase the nervous system side effects of remimazolam such as:
- dizziness
- drowsiness
- difficulty concentrating
Some people may also experience impairment in thinking and judgment.
You should avoid or limit the use of alcohol while being treated with remimazolam.
Do not use more than the recommended dose of remimazolam, and avoid activities requiring mental alertness such as driving or operating hazardous machinery until you know how the medication affects you.
Talk to your doctor or pharmacist if you have any questions or concerns.
Disease interactions
12 potential interactionsApplies to: 12 conditions, including Myasthenia Gravis, Urinary Retention, Drug Dependence, Glaucoma/Intraocular Hypertension, and Shock.
Altered Consciousness
Major:remimazolam
Remimazolam has a major potential interaction with Altered Consciousness.
Benzodiazepines should not be administered by injection to patients in shock or coma. The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.
Asphyxia
Major:remimazolam
Remimazolam has a major potential interaction with Asphyxia.
Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.
Drug Dependence
Major:remimazolam
Remimazolam has a major potential interaction with Drug Dependence.
Benzodiazepines have the potential to cause dependence and abuse. Tolerance as well as physical and psychological dependence can develop, particularly after prolonged use and/or excessive dosages. However, abrupt cessation following continual use of as few as 6 weeks at therapeutic levels has occasionally precipitated withdrawal symptoms. Addiction- prone individuals, such as those with a history of alcohol or substance abuse, should be under careful surveillance when treated with benzodiazepines. It may be prudent to refrain from dispensing large quantities of medication to these patients. After prolonged use or if dependency is suspected, withdrawal of benzodiazepine therapy should be undertaken gradually using a dosage- tapering schedule. If withdrawal symptoms occur, temporary reinstitution of benzodiazepines may be necessary.
Esophageal Obstruction
Major:Banflex
The orphenadrine in Banflex has a major potential interaction with Esophageal Obstruction.
Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive. The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis. Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.
Gastrointestinal Obstruction
Major:Banflex
The orphenadrine in Banflex has a major potential interaction with Gastrointestinal Obstruction.
Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive. The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis. Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.
Glaucoma/Intraocular Hypertension
Major:Banflex
The orphenadrine in Banflex has a major potential interaction with Glaucoma/Intraocular Hypertension.
Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive. The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis. Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.
Myasthenia Gravis
Major:Banflex
The orphenadrine in Banflex has a major potential interaction with Myasthenia Gravis.
Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive. The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis. Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.
Pulmonary Impairment
Major:remimazolam
Remimazolam has a major potential interaction with Pulmonary Impairment.
Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.
Renal Dysfunction
Moderate:remimazolam
Remimazolam has a moderate potential interaction with Renal Dysfunction.
Benzodiazepines are excreted by the kidneys and should be used with caution in patients with impaired renal function and end-stage kidney disease.
Respiratory Arrest
Major:remimazolam
Remimazolam has a major potential interaction with Respiratory Arrest.
Benzodiazepines may cause respiratory depression and apnea, usually when given in high dosages and/or by intravenous administration. However, some patients may be susceptible at commonly used dosages, including the elderly, debilitated or severely ill patients, those receiving other CNS depressants, and those with limited ventilatory reserve, chronic pulmonary insufficiency or other respiratory disorders. Therapy with benzodiazepines should be administered cautiously in these patients. Appropriate monitoring and individualization of dosage are particularly important, and equipment for resuscitation should be immediately available if the parenteral route is used. Benzodiazepines, especially injectable formulations, should generally be avoided in patients with sleep apnea, severe respiratory insufficiency, or hypoxia.
Shock
Major:remimazolam
Remimazolam has a major potential interaction with Shock.
Benzodiazepines should not be administered by injection to patients in shock or coma. The hypnotic and hypotensive effects of these agents may be prolonged and intensified in such patients.
Urinary Retention
Major:Banflex
The orphenadrine in Banflex has a major potential interaction with Urinary Retention.
Orphenadrine has mild anticholinergic activity, to which elderly patients are particularly sensitive. The manufacturer considers the use of orphenadrine to be contraindicated in patients with glaucoma, pyloric or duodenal obstruction, achalasia, prostatic hypertrophy, bladder neck obstruction, or myasthenia gravis. Orphenadrine should be used cautiously in other conditions that are likely to be exacerbated by anticholinergic activity, such as urinary retention and gastrointestinal obstructive disorders.
Report options
- Switch to professional interaction data
- Email this report to a friend, doctor, or patient
- Ask questions, find answers
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.